Navigation Links
New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
Date:4/18/2012

Lugano-CH/Aurora-US-CO/Geneva-CH, 18 April 2012 -- Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

The results of biomarker analyses of a recently reported clinical trial confirm that patients with unknown or negative mutation status should be treated with the standard chemotherapy first, they say.

The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and gemcitabine, against the standard reverse sequence. Erlotinib is a drug that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase.

The primary endpoint of the original TORCH study was overall survival and 900 patients were planned, however the study was stopped early as the first interim analysis showed that the erlotinib-first regimen was inferior to the standard approach.

In the new study, Dr Ming Tsao and colleagues conducted an exploratory analysis on the TORCH patient tumor samples that were available for analysis, looking for molecular biomarkers known to be potential predictors of benefit from EGFR inhibitors.

"Our results show a significant interaction in progression-free survival favoring treatment with erlotinib first in EGFR-mutated patients, and favouring first treatment with chemotherapy in EGFR wild type [non-mutated] patients," said Dr Tsao, from the Princess Margaret Hospital.

"However there was no significant interaction between treatment efficacy and overall survival. This shows that using erlotinib to treat patients with a mutated tumor is always effective, both in first and in second line; of course, it is much more convenient for these patients to re
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. On the safe side: Contact-free analysis of chemical substances
2. Fine-scale analysis of the human brain yields insight into its distinctive composition
3. Buy coal? New analysis shows purchasing fossil fuel deposits best way to fight climate change
4. Analysis of stickleback genome sequence catches evolution in action
5. A new application allows online statistical analysis of gene-expression data
6. New analysis of premature infants heartbeats, breathing could be cues for leaving NICU
7. Beyond the microscope: Identifying specific cancers using molecular analysis
8. Analysis of generalized linear mixed models
9. Psychemedics Awarded Patent Fundamental To Hair Analysis Drug Testing
10. Sweeping genetic analysis of rare disease yields common mechanism of hypertension
11. Elusive ultrafine indoor air contaminants yield to NIST analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... W. Finberg, MD, the Richard M. Haidack Professor of ... University of Massachusetts Medical School, is lead investigator on ... predicting how the influenza virus changes and evolves in ... This approach has promise for becoming a pivotal tool ...
... than 3,000 hybrid fish in his time as a graduate ... that has helped him create one of the most comprehensive ... key prediction in evolutionary biology. "We can see a ... new specialized species," said Martin, who with Professor Peter Wainwright ...
... crops such as miscanthus, whose high yields have led ... in producing ethanol, are now shown to have another ... in the environment. In a 4-year University of Illinois ... to typical corn-corn-soybean rotations, each of the perennial crops ...
Cached Biology News:A snapshot of pupfish evolution in action 2Lower nitrogen losses with perennial biofuel crops 2Lower nitrogen losses with perennial biofuel crops 3
(Date:5/1/2015)... - Softchoice, a leading North American IT solutions and managed services ... two Cisco® Partner Summit Country awards. Cisco ... Partner of the Year for Canada ... Montreal . "We are ... at this year,s conference," said David MacDonald , Softchoice,s ...
(Date:5/1/2015)... According to a new ... Consumables), by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), ... - Analysis & Global Forecast to 2019", published ... Production Market for the forecast period of 2014 ... $2.572 Billion by 2019 from $1.425 Billion in ...
(Date:4/30/2015)... April 30, 2015   Tamir Biotechnology , a ... update on its Ebola antiviral therapy program. ... TMR004, is currently being evaluated and considered by a ... against Ebola. During the first quarter of 2015, the ... To Accelerate The Evaluation of Potential Treatments and Vaccines ...
(Date:4/30/2015)... April 30, 2015 Oxford Finance LLC ("Oxford"), ... life sciences and healthcare services companies, today announced the ... agreement with Celula, Inc., a diagnostic testing company focused ... better patient care and improved outcomes.  Proceeds of the ... expand the commercialization of its products in the U.S. ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Oxford Finance Provides $10 Million Debt Financing to Celula 2
... 15 A panel of expert judges selected Nikon Instruments, ... second place among the top ten in The Scientist,s ... of invention, vision and utility. The award, the first-ever ... in the past year, acknowledges Nikon,s exclusive PFS system for ...
... Dec. 15 ADVENTRX Pharmaceuticals, Inc. (Amex: ... and commercializing proprietary product candidates primarily for the treatment ... range of strategic options, including the sale or disposition ... a strategic business merger and other transactions that maximize ...
... 15 BioMed Realty Trust, Inc.,(NYSE: BMR ) ... fourth,quarter 2008 dividend of $0.335 per share of common stock. ... common share. , BioMed ... dividend,of $0.46094 per share of the company,s 7.375% Series A ...
Cached Biology Technology:Nikon Instruments Perfect Focus System Wins Second Place in The Scientist's Top Innovations of 2008 Award 2ADVENTRX Exploring Strategic Options 2ADVENTRX Exploring Strategic Options 3ADVENTRX Exploring Strategic Options 4BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends 2
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Biology Products: